Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Catharina Ziekenhuis Eindhoven
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Ipsen
AstraZeneca
Sun Yat-sen University
Eastern Cooperative Oncology Group
Arcus Biosciences, Inc.
Alliance for Clinical Trials in Oncology
Akeso
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Summit Therapeutics
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Universität des Saarlandes
Jazz Pharmaceuticals
Akeso
AstraZeneca
National Cancer Institute (NCI)
SWOG Cancer Research Network
Bristol-Myers Squibb
Astellas Pharma Inc
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Universitätsmedizin Mannheim
NRG Oncology
NRG Oncology
NRG Oncology
Canadian Cancer Trials Group
TransThera Sciences (Nanjing), Inc.
Children's Oncology Group
Suzhou Transcenta Therapeutics Co., Ltd.
Merck Sharp & Dohme LLC
Charite University, Berlin, Germany
Revolution Medicines, Inc.
Sun Yat-sen University
City of Hope Medical Center
Gruppo Oncologico del Nord-Ovest
Incyte Corporation
Genfleet Therapeutics (Shanghai) Inc.
Hoffmann-La Roche
Maimónides Biomedical Research Institute of Córdoba